Vapotherm, Inc. (NYSE:VAPO – Get Rating) – Investment analysts at William Blair reduced their Q3 2022 earnings per share estimates for shares of Vapotherm in a note issued to investors on Wednesday, August 3rd. William Blair analyst M. Kaczor now anticipates that the company will post earnings of ($0.82) per share for the quarter, down from their prior estimate of ($0.74). William Blair has a "Market Perform" rating on the stock. The consensus estimate for Vapotherm's current full-year earnings is ($3.28) per share. William Blair also issued estimates for Vapotherm's Q4 2022 earnings at ($0.69) EPS, Q1 2023 earnings at ($0.59) EPS, Q2 2023 earnings at ($0.58) EPS, Q3 2023 earnings at ($0.58) EPS, Q4 2023 earnings at ($0.43) EPS and FY2023 earnings at ($2.18) EPS.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group cut Vapotherm from a "buy" rating to a "hold" rating and lowered their price target for the stock from $12.00 to $5.00 in a research report on Friday, May 6th. BTIG Research cut Vapotherm from a "buy" rating to a "neutral" rating in a research report on Thursday. Canaccord Genuity Group lowered Vapotherm from a "buy" rating to a "hold" rating and reduced their price objective for the company from $12.00 to $5.00 in a research note on Friday, May 6th. Finally, Piper Sandler reduced their price objective on Vapotherm from $2.50 to $2.00 and set an "underweight" rating for the company in a research note on Thursday. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company. Based on data from MarketBeat, Vapotherm has an average rating of "Hold" and a consensus target price of $4.75.

Vapotherm Stock Performance

Insider Buying and Selling at Vapotherm

In related news, Director Anthony L. Arnerich acquired 10,000 shares of Vapotherm stock in a transaction on Wednesday, June 1st. The stock was acquired at an average price of $3.06 per share, for a total transaction of $30,600.00. Following the purchase, the director now owns 53,374 shares of the company's stock, valued at approximately $163,324.44. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders purchased 35,000 shares of company stock worth $106,100. Insiders own 12.80% of the company's stock.

Hedge Funds Weigh In On Vapotherm

Several institutional investors and hedge funds have recently modified their holdings of the business. BNP Paribas Arbitrage SA increased its stake in shares of Vapotherm by 18.0% in the 4th quarter. BNP Paribas Arbitrage SA now owns 4,907 shares of the company's stock valued at $102,000 after purchasing an additional 747 shares in the last quarter. Taylor Frigon Capital Management LLC increased its stake in shares of Vapotherm by 1.3% in the 1st quarter. Taylor Frigon Capital Management LLC now owns 174,752 shares of the company's stock valued at $2,429,000 after purchasing an additional 2,218 shares in the last quarter. RiverVest Venture Management LLC increased its stake in shares of Vapotherm by 0.6% in the 4th quarter. RiverVest Venture Management LLC now owns 407,166 shares of the company's stock valued at $8,432,000 after purchasing an additional 2,535 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Vapotherm by 2.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 165,834 shares of the company's stock valued at $2,306,000 after purchasing an additional 3,209 shares in the last quarter. Finally, MetLife Investment Management LLC increased its stake in shares of Vapotherm by 60.7% in the 1st quarter. MetLife Investment Management LLC now owns 14,161 shares of the company's stock valued at $197,000 after purchasing an additional 5,351 shares in the last quarter. Hedge funds and other institutional investors own 69.67% of the company's stock.

Vapotherm Company Profile

(Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

See Also

• Get a free copy of the StockNews.com research report on Vapotherm (VAPO)
• Can Airbnb Still Thrive in a Recession?
• ConocoPhillips Shares Advance On Strong Q2 Revenue
• What to Expect from the Markets in a Recession
• MarketBeat: Week in Review 8/1 – 8/5
• How to Use High Beta Stocks to Maximize Your Investing Profits

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.